Gilead Sciences Inc (ASX:GILD)
79 USD
-0.450 0.566%Sponsored Reports
Previous Close (in USD) | 79.45 |
---|---|
Change | -0.450 0.566% |
52 W H/L (in USD) | 86.979/63.740 |
EBITDA (in USD) | 12665M |
PE Ratio | 182.69 |
Volume | 6122937 |
Diluted Eps TTM | 0.35 |
Total Assets (in USD) | 62125M |
---|---|
Total Liabilities (in USD) | 39376M |
Revenue TTM (in USD) | 27449.999M |
Cash (in USD) | 6085M |
Market Cap (in USD) | 79,659.647 M |
Revenue Per Share TTM | 22.000 |
Gross Profit TTM (in USD) | 21624M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Gilead Sciences Inc
Employees: 18000
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Mr. Daniel P. O'Day | Chairman & CEO | 1964 |
2. | Mr. Andrew D. Dickinson | Exec. VP & CFO | 1970 |
3. | Ms. Johanna Mercier | Chief Commercial Officer | 1970 |
4. | Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 1963 |
5. | Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer | 1962 |
6. | Ms. Jacquie Ross C.F.A. | VP of Investor Relations | NA |
7. | Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. | 1965 |
8. | Ms. Jyoti K. Mehra | Exec. VP of HR | 1976 |
9. | Dr. Michael Quigley Ph.D. | Sr. VP of Research Biology | NA |
10. | Dr. Linda Slanec Higgins Ph.D. | Sr. VP & Head of External Innovation | 1962 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - General
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
LLY
Eli Lilly and Company |
+19.820 2.108% | 945 | 103.140 | 46.729 | 16.878 | 48.243 | 17.429 | 69.108 |
JNJ
Johnson & Johnson |
+1.630 0.993% | 164.12 | 29.170 | 14.327 | 3.740 | 5.180 | 3.805 | 15.225 |
ABBV
AbbVie Inc |
+1.130 0.579% | 195.25 | 42.380 | 13.680 | 4.879 | 22.144 | 5.718 | 31.926 |
MRK
Merck & Company Inc |
+0.990 0.843% | 117.27 | 59.830 | 12.331 | 4.501 | 6.473 | 4.941 | 23.790 |
Income Statement
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Income Before Tax | 5814M | 8278M | 1669M | 5160M | 7799M |
Minority Interest | 26M | 24M | -34M | -22M | 5M |
Net Income | 4592M | 6225M | 89M | 5386M | 5455M |
Selling General Administrative | 5673M | 5246M | 5151M | 4381M | 4056M |
Gross Profit | 21624M | 20704M | 20117M | 17774M | 17274M |
Reconciled Depreciation | 2103M | 2050M | 1480M | 1404M | 1429M |
Ebit | 7330M | 7406M | 7029M | 4287M | 7447M |
Ebitda | 10393M | 9456M | 8509M | 6155M | 8876M |
Depreciation And Amortization | 3063M | 2050M | 1480M | 1868M | 1429M |
Operating Income | 7330M | 7406M | 7029M | 4287M | 8200M |
Other Operating Expenses | 16307M | 17210M | 14762M | 18162M | 13927M |
Interest Expense | 935M | 1001M | 984M | 995M | 1077M |
Tax Provision | 1248M | 2077M | 1580M | -204M | 2339M |
Interest Income | - | - | - | 227M | 964M |
Net Interest Income | -935M | -1001M | -984M | -995M | -1077M |
Income Tax Expense | 1248M | 2077M | 1580M | -204M | 2339M |
Total Revenue | 27281M | 27305M | 24689M | 22449M | 22127M |
Total Operating Expenses | 10650M | 10609M | 10190M | 13487M | 9074M |
Cost Of Revenue | 5657M | 6601M | 4572M | 4675M | 4853M |
Total Other Income Expense Net | -1516M | 872M | -5360M | 873M | 676M |
Net Income From Continuing Ops | 4566M | 6201M | 89M | 5364M | 5460M |
Net Income Applicable To Common Shares | 4592M | 6225M | 123M | 5386M | 5455M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Total Assets | 62125M | 63171M | 67952M | 68407M | 61627M |
Intangible Assets | 26454M | 28894M | 33455M | 33126M | 13786M |
Other Current Assets | 2374M | 1774M | 2141M | 2013M | 1440M |
Total Liab | 39376M | 41962M | 46888M | 50186M | 38977M |
Total Stockholder Equity | 22749M | 21209M | 21064M | 18221M | 22650M |
Other Current Liab | 11280M | 8059M | 9389M | 7796M | 6547M |
Common Stock | 1M | 1M | 1M | 1M | 1M |
Capital Stock | 1M | 1M | 1M | 1M | 1M |
Retained Earnings | 16304M | 15687M | 16324M | 14381M | 19388M |
Good Will | 8314M | 8314M | 8332M | 8108M | 4117M |
Other Assets | - | 1M | 5988M | 4799M | 3119M |
Cash | 6085M | 5412M | 5338M | 5997M | 11631M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 11280M | 11237M | 11610M | 11397M | 9759M |
Current Deferred Revenue | -2348M | - | - | - | - |
Net Debt | 18902M | 19818M | 21357M | 25405M | 12962M |
Short Term Debt | 1798M | 2273M | 1516M | 2757M | 2499M |
Short Long Term Debt | 1798M | 2273M | 1516M | 2757M | 2499M |
Short Long Term Debt Total | 24987M | 25230M | 26695M | 31402M | 24593M |
Other Stockholder Equity | -16332M | 5519M | 4656M | 3899M | 3176M |
Property Plant Equipment | - | 5475M | 5121M | 4967M | 4502M |
Total Current Assets | 16454M | 15227M | 15056M | 15816M | 31489M |
Long Term Investments | 1163M | 1245M | 1309M | 502M | 1488M |
Short Term Investments | 1179M | 973M | 1182M | 1411M | 12721M |
Net Receivables | 4660M | 4777M | 4493M | 4892M | 3582M |
Long Term Debt | 23189M | 22957M | 25179M | 28645M | 22094M |
Inventory | 3366M | 2820M | 2734M | 3014M | 2067M |
Accounts Payable | 550M | 905M | 705M | 844M | 713M |
Accumulated Other Comprehensive Income | 28M | 2M | 83M | -60M | 85M |
Non Currrent Assets Other | 5586M | 4016M | 5988M | 6390M | 7733M |
Non Current Assets Total | 45671M | 47944M | 52896M | 52591M | 30138M |
Capital Lease Obligations | - | - | - | - | - |
Long Term Debt Total | - | 22957M | 25179M | 28645M | 22094M |
Cash Flow
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Investments | -2466M | -3131M | 11948M | -2307M | 15279M |
Total Cashflows From Investing Activities | -2466M | -3131M | -14615M | -7817M | 14355M |
Total Cash From Financing Activities | -6469M | -8877M | 770M | -7634M | -12318M |
Net Income | 4566M | 6201M | 89M | 5364M | 5460M |
Change In Cash | 74M | -659M | -5634M | -6309M | 10352M |
Begin Period Cash Flow | 5338M | 5997M | 11631M | 17940M | 7588M |
End Period Cash Flow | 5412M | 5338M | 5997M | 11631M | 17940M |
Total Cash From Operating Activities | 9072M | 11384M | 8168M | 9144M | 8400M |
Depreciation | 2103M | 2050M | 1480M | 1404M | 1429M |
Other Cashflows From Investing Activities | -1798M | -3131M | -25913M | -4685M | -190M |
Dividends Paid | -3709M | -3605M | -3449M | -3222M | 2971M |
Change To Inventory | -310M | 11M | -195M | -95M | -310M |
Sale Purchase Of Stock | -1396M | -546M | -1583M | -1749M | -2900M |
Other Cashflows From Financing Activities | -173M | -145M | 8046M | -122M | -486M |
Capital Expenditures | 728M | 579M | 650M | 825M | 924M |
Change In Working Capital | -1763M | 489M | -1638M | -798M | -939M |
Other Non Cash Items | 5081M | 2125M | 7808M | 4636M | 1316M |
Free Cash Flow | 8344M | 10805M | 7518M | 8319M | 7476M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Vanguard Total Stock Mkt Idx Inv | 4 months ago | 39210005 |
2. | American Funds Income Fund of Amer A | 5 months ago | 34066365 |
3. | Vanguard Institutional 500 Index Trust | 4 months ago | 31699615 |
4. | Dodge & Cox Stock I | 5 months ago | 24371112 |
5. | Invesco QQQ Trust | 4 months ago | 23409636 |
6. | American Funds Washington Mutual A | 5 months ago | 20839642 |
7. | Capital Group Wash Mutual Invtrs Comp | 5 months ago | 20839642 |
8. | Performer (AFRIS) | 6 months ago | 17796366 |
9. | American Funds American Balanced A | 5 months ago | 16583231 |
10. | American Funds Capital Income Bldr A | 5 months ago | 15820423 |
11. | Fidelity 500 Index | 5 months ago | 15058752 |
12. | Capital Group American Mutual Comp | 5 months ago | 14922886 |
13. | American Funds American Mutual A | 5 months ago | 14922886 |
14. | SPDR® S&P 500 ETF Trust | 4 months ago | 14733144 |
15. | iShares Core S&P 500 ETF | 4 months ago | 12831965 |
16. | Vanguard Equity-Income Inv | 5 months ago | 10969940 |
17. | Capital Group Investment Co of Amer Comp | 5 months ago | 10522113 |
18. | American Funds Invmt Co of Amer A | 5 months ago | 10522113 |
19. | Vanguard Value Index Inv | 4 months ago | 10357717 |
20. | Health Care Select Sector SPDR® ETF | 4 months ago | 9082539 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | BlackRock Inc | 8 months ago | 122793011 |
2. | Vanguard Group Inc | 5 months ago | 114732575 |
3. | Capital World Investors | 5 months ago | 84497404 |
4. | Capital Research Global Investors | 5 months ago | 61246366 |
5. | State Street Corporation | 8 months ago | 59536425 |
6. | Dodge & Cox | 5 months ago | 33167487 |
7. | Geode Capital Management, LLC | 8 months ago | 25274185 |
8. | Goldman Sachs Group Inc | 8 months ago | 19283234 |
9. | Wellington Management Company LLP | 8 months ago | 18630134 |
10. | Morgan Stanley - Brokerage Accounts | 8 months ago | 17801718 |
11. | FMR Inc | 8 months ago | 17097648 |
12. | NORGES BANK | 8 months ago | 16067445 |
13. | Bank of New York Mellon Corp | 8 months ago | 15498906 |
14. | Northern Trust Corp | 8 months ago | 14025898 |
15. | Legal & General Group PLC | 8 months ago | 12462123 |
16. | Amvescap Plc. | 8 months ago | 11648801 |
17. | Nuveen Asset Management, LLC | 8 months ago | 11535475 |
18. | Royal Bank of Canada | 8 months ago | 10637491 |
19. | Amundi | 8 months ago | 10520554 |
20. | Dimensional Fund Advisors, Inc. | 5 months ago | 10144205 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).